Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis B or C: A Systematic Review and Meta-Analysis

<div>Forest plots depicting the pooled value of all-grade irAEs of (a) uninfected patients and patients with HCV and HBV and (b) patients with hepatitis.</div>

Journal of Oncology

fig6

Figure 6

Figure 6: Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis B or C: A Systematic Review and Meta-Analysis 